IRWD
Ironwood Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$4.26
−0.70%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
3.6x
EV/EBITDA
4.2x
Market Cap
$703.92M
MomentumView details →
1D Return
−0.70%
YTD Return
+26.26%
RSI (14)
51.2
ValuationView details →
P/E (Fwd)
3.6x
EV/EBITDA
4.2x
Market Cap
$703.92M
RSI (14)
51.2
MomentumView details →
1D Return
−0.70%
YTD Return
+26.26%
SummaryUpdated Jun 1, 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is a Boston-based healthcare company founded in 1998 that specializes in developing and commercializing treatments for gastrointestinal disorders. Originally incorporated as Microbia, Inc., the company changed its name to Ironwood Pharmaceuticals in 2008 and went public in 2010. The company has evolved from a research-focused biotechnology firm into a commercial-stage pharmaceutical company with a primary focus on gastrointestinal therapeutics, anchored by its flagship product LINZESS and a promising pipeline candidate apraglutide for rare diseases.
Similar companies
Latest newsMore news →
Ironwood Pharmaceuticals started enrollment in its confirmatory Phase III study of apraglutide.29d agoIronwood Pharmaceuticals reported Q2 2026 total revenue of $113 million, GAAP net income of $51 million, and adjusted EBITDA of $83 million, with LINZESS US net sales of $282 million for the quarter.30d ago